Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Toxicol (Phila). 2013 Jul;51(6):487-92. doi: 10.3109/15563650.2013.802795. Epub 2013 Jun 4.

Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series.

Author information

1
Medical Toxicology Centre, Institute of Cellular Medicine, Newcastle University, Newcastle, UK. simon.hill@ncl.ac.uk

Abstract

CONTEXT:

4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) is a N-methoxybenzyl-substituted phenethylamine with potent serotoninergic effects. We describe seven cases of analytically confirmed toxicity due to the recreational use of 25I-NBOMe in the United Kingdom.

CASE SERIES:

Seven patients, all young adult males, presented to hospitals in the northeast of England with clinical toxicity after recreational drug use in January 2013. Clinical features included tachycardia (n = 7), hypertension (4), agitation (6), aggression, visual and auditory hallucinations (6), seizures (3), hyperpyrexia (3), clonus (2), elevated white cell count (2), elevated creatine kinase (7), metabolic acidosis (3), and acute kidney injury (1). LC-MS/MS analysis identified 25I-NBOMe as the main active substance in the plasma of all seven cases.

CONCLUSIONS:

Severe clinical toxicity may occur following recreational use of 25I-NBOMe, with stimulant and serotoninergic features predominating. Clinicians should be alert to this substance, in view of its emergence in Europe as well as in the United States.

PMID:
23731373
DOI:
10.3109/15563650.2013.802795
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center